Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of ASC42 in healthy subjects
NCT04679129Phase 1Completed
- Sponsor
- Gannex Pharma Co., Ltd.
- Start
- Nov 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of asc42 in Nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC) (4 arms), sponsored by Gannex Pharma Co., Ltd. Primary endpoint: Incidence of Treatment-Emergent Adverse Events up to 21 days. Started Nov 2020; status: completed.
02
Drugs
asc42
03
Conditions
Nonalcoholic steatohepatitis (NASH)primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT04679129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04679129.